http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018250317-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f25d9b7e1fadfcbe0f4127cc79658aea |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_135359511ad03b557d321c9202cfb3d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_746a4c829d24f0fbf5eb6c42a8445932 |
| publicationDate | 2018-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2018250317-A1 |
| titleOfInvention | Muparfostat for use in treating patients with hepatitis virus-related hepatocellular carcinoma after surgical resection |
| abstract | Muparfostat for use in reducing intrahepatic tumor recurrence and increasing disease-free survival period in a hepatocellular carcinoma patient with microvascular invasion after curative liver resection, while excluding HCC patients with no vascular invasion and HCC patients with macrovascular invasion, is disclosed. The hepatocellular carcinoma patient with microvascular invasion is identified by examining a resected liver tumor sample from the HCC patient for the presence of microvascular invasion in the sample. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113160911-A |
| priorityDate | 2017-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 128.